About ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)
The present work examined the potential of making use of ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant in addition palbociclib. ARV-825 was effective in both of those p53 wild-sort (WT) breast tumor cells and in cells lacking useful p53 either alone or in combination with tamoxifen, even though the effectiveness of